September PBS listing likely for dabigatran
A spokesperson for manufacturer Boehringer Ingelheim told Medical Observer they were "extremely confident" it would be PBS listed on 1 September for the indication of stroke prevention in patients with non-valvular atrial fibrillation.
However, a spokesperson for the health department could not confirm the listing date but said announcements would be made in due course.
BMS and Pfizer, sponsors of apixaban (Eliquis) also told MO they were confident of securing PBS listing from 1 September.
PBS listing of dabigatran (Pradaxa) for the indication was initially recommended in March 2011 by the Pharmaceutical Benefits Advisory Committee (PBAC).
In September 2011, the government announced a review of all anticoagulants, including dabigatran.
The review, conducted by former PBAC chair Professor Lloyd Sansom, took more than a year to complete and found more information was needed on the cost effectiveness of new oral